Secondary Logo

Share this article on:

Saccharomyces cerevisiae Fungemia After Saccharomyces boulardii Treatment in Immunocompromised Patients

Riquelme, Arnoldo J. M.D.; Calvo, Mario A. M.D.; Guzmán, Ana M. M.D.; Depix, María S.; García, Patricia M.D.; Pérez, Carlos M.D.; Arrese, Marco M.D.; Labarca, Jaime A. M.D.

Journal of Clinical Gastroenterology: January 2003 - Volume 36 - Issue 1 - p 41-43
Alimentary Tract: Case Reports

Saccharomyces boulardii is widely used as a probiotic compound. Clinical data suggest that this agent is safe and effective. We report two cases of fungemia caused by S. cerevisiae occurring in immunosuppressed patients treated orally with S. boulardii. Molecular typing confirmed clonality in isolate strains from patients and the S. boulardii capsule. Physicians caring for immunosuppressed patients must be aware of this potential serious complication of probiotic use.

From the Departments of Internal Medicine (M.A.C., C.P., J.A.L.) and Gastroenterology (A.J.R., M.A.), and the Clinical Microbiology Laboratory (A.M.G., M.S.D., P.G.), Universidad Católica de Chile, School of Medicine, Santiago, Chile.

Submitted April 4, 2002.

Accepted June 4, 2002.

Address correspondence and reprint requests to Dr. Jaime Labarca, Department of Medicine, Pontificia Universidad Católica de Chile School of Medicine, Marcoleta #357, PO Box Casilla 114-D, Santiago, Chile. E-mail: jlabarca@med.puc.cl.

Probiotics such as Lactobacillus GG, Bifidobacterium spp., and Saccharomyces boulardii have been shown to be useful in treating a variety of diarrheal disorders, including rotavirus infection, antibiotic-associated diarrhea, Clostridium difficile–associated diarrhea, and traveler's diarrhea. 1–4 The use of these agents has traditionally been regarded as safe, and reports of complications are rare. 5–7 We report two cases of S. cerevisiae fungemia related to the use of S. boulardii as treatment of antibiotic-associated diarrhea.

Back to Top | Article Outline

CASE REPORTS

Case 1

A 42-year-old woman with end-stage renal disease secondary to diabetes mellitus type I underwent kidney–pancreas transplantation in 1997. She subsequently received standard immunosuppressive therapy with cyclosporine (Neoral; Novartis Pharmaceuticals, East Hanover, NJ, 150 mg/d orally), mycophenolate mofetil (Cellcept; Roche Laboratories, Nutley, NJ, 1 g/d orally), and prednisone (5 mg/d orally). In September 2000, she was admitted with a soft tissue infection of her right foot and was treated with parenteral ciprofloxacin and metronidazole. After 4 days of antibiotics, she developed significant diarrhea (400 cc/24 hours) and metronidazole was switched to an oral route after a positive toxin A assay for C. difficile. After 10 days without clinical response, S. boulardii (Perenteryl; Merck, Ñuñoa-Santiago, Chile) 250 mg four times daily orally for 7 days was added to the treatment, with good clinical response. On day 20 of hospitalization, she developed a fever. S. cerevisiae grew out from two simultaneous blood cultures after 5 days of incubation. Fluconazole was then given at dosage of 400 mg/d intravenously for 8 days and was followed by 13 days of oral treatment, with excellent clinical response. She was discharged on day 51 with follow-up in our outpatient infectious disease clinic.

Back to Top | Article Outline

Case 2

A 41-year-old man with a history of 3 weeks of progressive tetraparesis and confusion was admitted with a diagnosis of meningoencephalomyelitis secondary to Treponema pallidum and Mycobacterium tuberculosis (Venereal Disease Research Laboratory–positive 1:4, cerebrospinal fluid–positive for M. tuberculosis by polymerase chain reaction [PCR]). The patient was newly diagnosed with HIV, with a CD4 count of 14 cells/mm3. Simultaneously, treatment was begun for syphilis (penicillin G intravenously), M. tuberculosis (isoniazid, rifampin and ethambutol for 6 months), and HIV (zidovudine, lamivudine, and efavirenz).

The patient then developed diarrhea (500 cc/24 hours) with a negative C. difficile toxin A assay. After 15 days of persistent diarrhea, he received treatment with S. boulardii (Perenteryl) 250 mg three times daily for 20 days, with a significant clinical response. Fifteen days after probiotic treatment was discontinued, the patient developed a fever. S. cerevisiae grew out from two simultaneous blood cultures. Empiric treatment with amphotericin B had been started and was continued for a total dose of 1,100 mg. He is currently seen in the outpatient infectious disease clinic. After 6 months of antiretroviral treatment, his HIV viral load was undetectable and his CD4 count was 255 cells/mm3.

To further characterize the described clinical cases, we performed cultures of capsules containing 250 mg of lyophilized S. boulardii (Perenteryl, 250-mg equivalent to 5 × 1,085 × 1010 live cells). S. cerevisiae was isolated after 5 days of incubation. In pulsed-field gel electrophoresis assays, samples isolated from patients and strains obtained from a Perenteryl capsule showed identical electrophoretic patterns using Not I restriction enzyme, which were different from the banding pattern resulting from the digestion of a control strain (Fig. 1).

FIG. 1.

FIG. 1.

Back to Top | Article Outline

DISCUSSION

S. boulardii has been used in the treatment of antibiotic-associated diarrhea and in the therapy of recurrent C. difficile diarrhea. 2,4–6 This probiotic is administered orally in the form of capsules containing lyophilized S. boulardii and is considered a safe medication.

Recently, several reports of S. cerevisiae fungemia associated with the use of S. boulardii have been published. 8–16 A debate exists concerning the genotyping identity of S. cerevisiae and S. boulardii. Two published case reports and the two cases presented here showed identity between the strains isolated from blood cultures and the strains isolated from probiotic capsules using pulsed-field gel electrophoresis. 8,15 Although Mc Farland 17 has proposed that S. cerevisiae and S. boulardii are different microorganisms with taxonomic, metabolic, and molecular differences, McCullough et al. 18 showed that isolates of S. boulardii were not separable from authentic isolates of S. cerevisiae using restriction fragment-length polymorphisms (RFLPs) of the PCR-amplified intergenic transcribed spacer regions. Moreover, RFLP analysis of cellular DNA with EcoRI showed that all analyzed strains of S. boulardii had identical patterns and were similar to other authentic S. cerevisiae isolates tested. Thus, it can be stated that S. boulardii strains are asporogenous strains of the species S. cerevisiae and therefore are not representatives of a distinct and separate species. 18 This is also supported by a recent study using microsatellite typing as a new tool for identification of S. cerevisiae strains. 19 These observations also explain the isolation of S. cerevisiae after culture of capsules containing 250 mg of lyophilized S. boulardii.

S. cerevisiae fungemia was first reported in 1970 in a patient with a prosthetic mitral valve. 20 Since then, many other fungemia cases caused by this yeast have been reported. 8–16,21–29 Although S. cerevisiae is considered a safe and nonpathogenic biotherapeutic agent, several reports show that this fungus may indeed cause severe infections with a wide clinical spectrum, including unexplained fever, fungemia, endocarditis, pneumonia, liver abscess, peritonitis, and septic shock. Review of published cases indicates that populations at risk are mainly elderly or immunocompromised patients with very low risk for immunocompetent subjects. Only nine cases related to the oral administration of S. boulardii have been reported. 8–16 These cases are summarized in Table 1. As expected, most of the patients reported were immunosuppressed because of HIV infection, use of corticosteroids or immunosuppressive agents, neutropenia, bone marrow transplantation, and neonate state. 8–16 However, there are two reports of fungemia in critically ill patients with no previous severe immunosuppression. 11,12 The two patients reported here had severe immunosuppressive underlying disease, such as HIV infection in IIIC stage and kidney–pancreas transplantation.

TABLE 1

TABLE 1

Most cases of S. cerevisiae fungemia related to oral administration of S. boulardii have been treated with conventional therapy, such as amphotericin B or fluconazole. There have been no reported deaths caused by this condition. We treated one patient with amphotericin B and the other with fluconazole, both with successful outcomes.

S. boulardii and other probiotics are increasingly being used in routine clinical practice to treat diarrheal disorders. Complications seen in the two patients described here, along with previous reports (Table 1), indicate that caution is warranted in treating certain populations (e.g., HIV-infected and transplant patients, neonates, patients with malnutrition, and any other disease associated with a immunosuppressed state).

Back to Top | Article Outline

Acknowledgment:

The authors thank Meredith Turetz, M.D., for her critical review of the manuscript.

Back to Top | Article Outline

REFERENCES

1. Phuapradit P, Varavithya W, Vathanophas K, et al. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai 1999; 82(Suppl 1):S43–8.
2. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000; 95(Suppl 1):S11–3.
3. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999; 135:564–8.
4. Cervetto JL. Antibiotic-induced diarrhea: recent findings about Clostridium difficile. Acta Gastroenterol Latinoam 1996; 26:251–4.
5. Lewis SJ, Potts LF, Barry RE. The lack of effect of Saccaromyces boulardii in the prevention of antibiotic-related diarrhea in elderly patients. J Infect 1998; 36:171–4.
6. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96:981–8.
7. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104:1108–15.
8. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105:71–2.
9. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. Ped Gastroenterol Nutr 1995; 21:113–5.
10. Perapoch J, Planes AM, Querol A, et al. Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura. Eur J Clin Microbiol Infect Dis 2000; 19:468–70.
11. Rijnders BJ, Van Wijngaerden E, Verwaest C, et al. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26:825.
12. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28:930.
13. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving ultra levure therapy. Clin Infect Dis 1998; 27:222–3.
14. Cesaro S, Chinello P, Rossi L, et al. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000; 8:504–5.
15. Viggiano M, Badetti C, Bernini V, et al. Saccharomyces boulardii fungemia in a patient with severe burn. Ann Fr Anesth Reanim 1995; 14:356–8.
16. Zunic P, Lacotte J, Pegoix M, et al. Saccharomyces boulardii fungemia. Apropos of a case. Therapie 1991; 46:498–9.
17. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996; 22:200–1.
18. McCullough MJ, Clemons KV, McCusker JH, et al. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998; 36:2613–7.
19. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001; 39:551–9.
20. Stein P, Folkens A, Hruska K. Saccharomyces fungemia. Chest 1970; 58:173–5.
21. Hannequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19:16–20.
22. Cairoli R, Marenco P, Perego R, et al. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant 1995; 15:785–6.
23. Fiore NF, Conway JH, West KW, et al. Saccharomyces cerevisiae infections in children. Pediatr Infect Dis 1998; 17:1177–9.
24. Eddy JT, Stamatakis MK, Makela EH. Saccharomyces boulardii fungemia for the treatment of Clostridium difficile associated colitis. Ann Pharmacother 1997; 31:919–21.
25. Oriol A, Ribera JM, Arnal J, et al. Saccharomyces cerevisiae septicemia in a patient with myelodisplastic syndrome. Am J Hematol 1993; 43:325–6.
26. Manzella JP, Shaffer S, Agarwal N, et al. Saccharomyces cerevisiae fungemia in a multiply traumatized patient. J Trauma 1989; 29:129–30.
27. Sethi N, Mandell W. Saccharomyces fungemia in a patient with AIDS. N Y State J Med 1988; 88:278–9.
28. Cimolai N, Gill MJ, Church D. Saccharomyces cerevisiae fungemia: case report and review of the literature. Diagn Microbiol Infect Dis 1987; 8:113–7.
29. Sheppard DC, Rene P, Harris AD, et al. Simple strategy for direct identification of medically important yeast species from positive blood culture vials. J Clin Microbiol 1999; 37:2040–1.
Keywords:

Saccharomyces cerevisiae fungemia; Saccharomyces boulardii; Immunocompromised patients

© 2003 Lippincott Williams & Wilkins, Inc.